TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19.
COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.
MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.

PORRIÑO, SPAIN, and NEW YORK, U.S. — JULY 14, 2021 — Spanish biopharmaceutical company Biofabri and IAVI today announced their intention to partner on efficacy trials of the tuberculosis (TB) vaccine candidate MTBVAC.

Read more...